Skip to main content
BJDX
NASDAQ Industrial Applications And Services

Bluejay Diagnostics Extends Cash Runway to Q2 2027, Reports $4.2M Net Loss

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$1.05
Mkt Cap
$1.086M
52W Low
$0.83
52W High
$16.68
52W Position info
27% above low
Off High info
94% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

BJDX sits 27% above its 52-week low of $0.83 on light trading volume (0.1× avg).

Summary

Bluejay Diagnostics extended its cash runway to Q2 2027 after raising $8.5 million in June, but still needs $10-14 million more and faces ongoing going concern and Nasdaq delisting risks.


Key Events · Earnings and Guidance · BJDX

  • Cash Runway Extended to Q2 2027

    Cash and cash equivalents rose to $9.6 million as of June 30, 2026, from $5.2 million at year-end 2025, extending the estimated runway from Q3 2026 to Q2 2027.

  • Net Loss of $4.2 Million

    The company reported a net loss of $4.2 million for the six months ended June 30, 2026, compared to $3.8 million in the prior year period.

  • Additional Capital Needed

    Management expects to raise between $10.0 million and $14.0 million by the end of fiscal 2027 to fund commercialization and manufacturing scale-up.

  • SYMON-II Enrollment Completed

    Patient enrollment for the SYMON-II clinical validation study for IL-6 was completed in July 2026, with a 510(k) submission targeted for the first half of 2027.


Analysis · BJDX · Industrial Applications And Services

Bluejay Diagnostics reported a net loss of $4.2 million for the first half of 2026, but the key development is the extension of its cash runway. The company now estimates its $9.6 million in cash will fund operations through the second quarter of 2027, a significant improvement from the prior estimate of only through Q3 2026. This extension is directly tied to the $8.5 million private placement closed in June 2026. However, the company still expects to need an additional $10-14 million by the end of 2027, and the going concern warning remains in place. The filing also highlights progress on the SYMON-II clinical trial, with patient enrollment completed in July 2026, and a new US manufacturing agreement with Argonaut. The stock trades near $1.05, and the company faces a new Nasdaq delisting risk if a proposed $5 million minimum market value rule is approved.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BJDX was trading at $1.05 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.1M. The 52-week trading range was $0.83 to $16.68. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BJDX - Latest Insights

BJDX
Nov 12, 2026, 5:00 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $2.61
Real-time Price: $2.63 info
Change: +$0.025 (+0.96%) info
Market Cap: $2.938M info
BJDX
Oct 30, 2026, 10:30 AM EDT
Source: ACCESS Newswire
Importance Score:
7
Price at Filing: $0.4615
Real-time Price: $2.63 info
Change: Reverse Stock Split info
Market Cap: $2.938M info
BJDX
Aug 13, 2026, 7:56 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.03
Real-time Price: $2.63 info
Change: Reverse Stock Split info
Market Cap: $2.938M info
BJDX
Aug 13, 2026, 6:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.05
Real-time Price: $2.63 info
Change: Reverse Stock Split info
Market Cap: $2.938M info
BJDX
Jul 22, 2026, 5:25 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.14
Real-time Price: $2.63 info
Change: Reverse Stock Split info
Market Cap: $2.938M info